Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: Complementary test of ZEBRA protein and early antigens p54 and p138

Citation
R. Dardari et al., Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: Complementary test of ZEBRA protein and early antigens p54 and p138, J CLIN MICR, 39(9), 2001, pp. 3164-3170
Citations number
31
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Microbiology
Journal title
JOURNAL OF CLINICAL MICROBIOLOGY
ISSN journal
0095-1137 → ACNP
Volume
39
Issue
9
Year of publication
2001
Pages
3164 - 3170
Database
ISI
SICI code
0095-1137(200109)39:9<3164:ARTREV>2.0.ZU;2-Y
Abstract
Serological tests based on the antibodies directed against the Epstein-Barr virus early antigen (EA) and viral capsid antigen (VCA), which have been r ecognized as tumor markers for nasopharyngeal carcinoma (NPC), are routinel y used to help in the diagnosis of this malignancy. The detection of these antibodies reveals very low titers, found only in a small proportion of you ng compared with older NPC patients. This is a problem for the diagnosis of NPC, especially among Maghrebians, among whom young people are also affect ed, and emphasizes the necessity to search for more reliable markers. The p resent study reports results of immunoglobulin G (IgG) and IgA responses of NPC patients to recombinant EA antigens p54 (BMRF1) and p138 (BALF2), VCA complex antigens p18 (BFRF3) and p23 (BLRF2), and EBNA antigen p72 (BKRF1). Our results show that IgA-EA-p54 and -p138 (IgA-EA-p54+138) antibodies hav e a diagnostic value for detection of NPC (70%), compared with IgA-VCA-p1823 and IgA-EBNA-p72, which have limited diagnostic value, especially in you ng. patients. It is also noteworthy that IgA-EA-p54+138 can detect a high p ercentage (64%) of NPC cases negative by immunofluorescence. These results, however, clearly show that a single test cannot achieve the objective of d etecting all NPC patients, and it seems advisable to combine different test s for the diagnosis of NPC., The combination of IgG-ZEBRA with IgA-EA-p54+1 38 improved the sensitivity of detection of NPC to 95% in the overall NPC p opulation. The use of IgA-EA-p54+138 in combination with IgG-ZEBRA will fac ilitate detailed studies on the pattern of antibody response, which may res ult in the development of useful serological markers to guide the treatment of NPC.